Literature DB >> 7710638

Potential suitability of Na+/K(+)-transporting ATPase in pre-screens for anti-cancer agents.

K R Repke1, R Schön, R Megges, J Weiland, E Nissen, E Matthes.   

Abstract

Twenty-five compounds [digitalis (generic name for cardenolides, bufadienolides and their glycosides) representatives and derivatives, various steroids as well as some customary carcinostatics] have been compared in terms of their potency to suppress the proliferation of Ehrlich mouse ascites carcinoma (EMAC) cells and to inhibit the activity of Na/K-ATPase from EMAC cells and from human cardiac muscle. The inhibitor susceptibilities of the Na/K-ATPase isoforms of EMAC and cardiac muscle are very different, in favour of the cardiac muscle with the digitalis-like acting steroids, whereas they are quite similar with the digitalis-unlike acting compounds. Whereas the K0.5 values for the inhibition of EMAC Na/K-ATPase display the expected dependence on steroid structure, the IC50 values for the suppression of EMAC cell proliferation all lie within a narrow concentration range. With ouabain, the IC50 value for the suppression of proliferation of oestrogen receptor-negative, human mammary carcinoma (MCA) cells is four orders of magnitude higher than the K0.5 value for inhibition of the activity of human cardiac muscle Na/K-ATPase. In contrast to this effectivity order, some synthetic derivatives of digitalis steroids develop primarily antiproliferative potency.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7710638

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  2 in total

1.  "The Lower Threshold" phenomenon in tumor cells toward endogenous digitalis-like compounds: Responsible for tumorigenesis?

Authors:  Heidrun Weidemann
Journal:  J Carcinog       Date:  2012-02-17

2.  Digitoxin medication and cancer; case control and internal dose-response studies.

Authors:  J Haux; O Klepp; O Spigset; S Tretli
Journal:  BMC Cancer       Date:  2001-08-10       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.